Sanofi India schedules board meeting on Aug 4 to approve Q2 and H1 unaudited results

What Sanofi India announced

Sanofi India Ltd informed the Bombay Stock Exchange that its Board of Directors will convene on 4 August 2026. The primary agenda is to consider and approve the unaudited financial results for the quarter and the half‑year ended 30 June 2026. The notice was filed on 20 July 2026.

Board meeting details

• Date of meeting: 04 August 2026
• Location: Company’s registered office (as per standard practice, not specified in the notice)
• Agenda: Review and approval of unaudited financial statements for Q2 2026 and H1 2026.
• Filing timestamp: 2026‑07‑20T06:48:19Z (BSE submission time).

The filing does not disclose the exact time of the meeting nor the composition of the quorum, which are typically communicated in a separate circular to shareholders.

Scope of the unaudited results

The notice references two reporting periods:

1. Quarter ended 30 June 2026 – representing the second fiscal quarter of FY 2026‑27.
2. Half‑year ended 30 June 2026 – covering the first six months of the same fiscal year.

Unaudited results are preliminary figures prepared by management and are subject to audit verification. They provide investors with an early view of the company’s performance before the audited statements are released.

Key facts at a glance

Why this matters for investors

The board’s approval of unaudited results is a regulatory requirement that signals the company’s readiness to disclose its financial performance for the stated periods. While the figures are not yet public, the approval process ensures that the results will soon be available to shareholders and analysts, enabling them to assess revenue trends, profitability, and cash‑flow health. The timing also aligns with typical quarterly reporting cycles in India, suggesting that the audited results are likely to follow in the subsequent weeks.

Conclusion

Sanofi India’s board is set to meet on 4 August 2026 to approve its unaudited Q2 and H1 2026 financial results. The filing provides the essential dates and scope but does not include the actual numbers. Investors should await the formal release of the results after board approval for a complete view of the company’s performance.